 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- E6742 / Eisai
SAFETY, PHARMACOKINETICS, BIOMARKER, AND EFFICACY OF E6742, A DUAL ANTAGONIST OF TOLL-LIKE RECEPTOR 7 AND 8, IN A FIRST-IN-PATIENT PHASE1/2 STUDY IN SYSTEMIC LUPUS ERYTHEMATOSUS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_818;
P1/2
In addition, E6742 provided a markedly improved IGS response, and sufficient efficacy signals regardless the short treatment duration. These results provide the first clinical evidence to suggest that E6742 as a first-in-class TLR7/8 inhibitor, could potentially be beneficial for SLE, and support the longer-term, larger clinical trials of E6742.
- || E6742 / Eisai
Review, Journal, IO biomarker: A new therapeutic target for systemic lupus erythematosus: the current landscape for drug development of a toll-like receptor 7/8 antagonist through academia-industry-government collaboration. (Pubmed Central) - Sep 29, 2023
P1, P1/2
One of the potential benefits of this program is to conduct academia-led clinical research to identify specific biomarkers for E6742 in parallel with clinical studies (UMIN000042037). The aim of this review is to present current progress within the strategic collaboration of the AMED CiCLE program that optimize clinical development for patients with SLE.
- || E6742 / Eisai
P1 data, PK/PD data, Journal: First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers. (Pubmed Central) - Apr 4, 2023
In addition to safety and good tolerability, this study demonstrated cytokine concentrations in cultured peripheral blood in response to E6742 were suppressed in a dose-dependent manner. Further clinical studies targeting systemic lupus erythematosus patients are currently underway.
- || E6742 / Eisai
Enrollment open: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants (clinicaltrials.gov) - Mar 18, 2022
P1/2, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
Further clinical studies targeting systemic lupus erythematosus patients are currently underway. Not yet recruiting --> Recruiting
- || E6742 / Eisai
New P1/2 trial: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants (clinicaltrials.gov) - Mar 14, 2022
P1/2, N=24, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- || E6742 / Eisai
Trial completion: A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants (clinicaltrials.gov) - Jul 20, 2021
P1, N=24, Completed, Sponsor: Eisai Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed
- || E6742 / Eisai
Enrollment open: A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants (clinicaltrials.gov) - Mar 9, 2021
P1, N=24, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- || E6742 / Eisai
New P1 trial: A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants (clinicaltrials.gov) - Dec 23, 2020
P1, N=24, Not yet recruiting, Sponsor: Eisai Co., Ltd.
- | E6742 / Eisai
Trial completion: Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects (clinicaltrials.gov) - Sep 7, 2018
P1, N=72, Completed, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || E6742 / Eisai
Enrollment closed, Trial primary completion date: Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects (clinicaltrials.gov) - Nov 9, 2017
P1, N=56, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Oct 2017
- | E6742 / Eisai
New P1 trial: Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects (clinicaltrials.gov) - Mar 16, 2017
P1, N=48, Recruiting, Sponsor: Eisai Inc.